Apolipoprotein B emerges as best lipid predictor for Myocardial Infarction risk
The risk of myocardial infarction in patients with and without atherosclerosis is best predicted by the number of apolipoprotein B (apoB)-containing lipoproteins, and this risk is independent from the lipid content and type of lipoproteins typically measured and targeted for therapy, according to a new analysis.
The results, which showed that only apoB was associated with the risk of MI in a model that fully adjusted for other lipids and clinical factors, suggest that apoB "may be the primary driver of atherosclerosis" and that drug therapy should target all apoB-containing lipoproteins to reduce the risk of adverse cardiovascular events.
For more details, check out the full story on the link below:
ApoB More Accurate Than LDL Or Non-HDL Cholesterol In Predicting Future MI Risk, JAMA Study
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.